John S. Douglas, MD

Emory Clinic

Director, Interventional Cardiology Fellowship Program

Professor of Medicine

Emory Healthcare Network Physician
Cardiology (Board certified since 1975)
Internal Medicine (Board certified since 1972)
Interventional Cardiology (Board certified since 1999)
Areas of Clinical Interest:
cardiac catheterization
cardiology-beta radiation
cardiology - interventional
cardiovascular disease
Office(s) Locations:
Emory Heart & Vascular Center at Clifton
1365 Clifton Road
Atlanta, GA 30322
404 778-5299
Hospital Affiliation(s):
Emory University Hospital
Year Started Practicing: 1972
Year Started Practicing at Emory: 1974
Organizational Memberships:
Dekalb Medical Society
Society for Cardiac Angiography and Interventions
Society for Cardiac Angiography and Intervention Board of Trustees
Major or Recent Publications:

Vassiliades TA, Kilgo PD, Douglas JS et al, 2010. Hybrid coronary revascularization versus off-pump coronary artery bypass: a prospective evaluation. Innovations, technology and techniques in cardiothoracic and vascular surgery. January 2010.

Leon MB, Mauri L, Popma JJ et al, 2010. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 6:543-54.

Douglas JS Jr, 2009. Are our patients better off with drug-eluting stents in saphenous vein grafts? J Am Coll Cardiol Intv 2:1113-1115.

Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O’Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, et al, 2009. Late safety, efficacy, and cost-effectiveness of zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Elutint Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 12:1208-18.

Ghazzal ZB, Dhawan SS, Sheikh A, Douglas JS, et al, 2009. Usefulness of serum high-density liproprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. A J Cardiol 7:902-6.

Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Douglas JS Jr, et al, 2007. 2007 Chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116:2762-72.

Zhang Z, Foster JK, Kolm P et al, 2006. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implanation: results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 4:770-776.

Douglas JS Jr; 2007. Pharmacologic Approaches To Restenosis Prevention. Am J Cardiol 100:10K-16K.

America's Top Doctors, 2001-2011
Atlanta's Top Doctors, 2001-2011

Best Doctor's in America, 2001 - 2011

Atlanta's Top Doctor's, 2001 - 2011
Atlanta Magazine
Medical School
Washington University School of Medicine, Seattle, WA

University of North Carolina School of Medicine, Chapel Hill, NC

University of North Carolina School of Medicine, Chapel Hill, NC
Grady Health Systems, Atlanta, GA

Emory University Hospital, Atlanta, GA